clock.bio develops a platform to decode the rejuvenation genome and validate interventions that reverse cellular aging. The company integrates proprietary technologies, including the geneAge Atlas and AI-driven imAge measurement, for high-throughput target discovery and measurement. This systematic approach aims to translate rejuvenation biology into topical, nutraceutical, and systemic therapeutics to extend human healthspan.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Modeling human aging and identifying rejuvenation mechanisms is challenging due to the complexity of the aging process and the limitations of traditional cell culture models. Current approaches often rely on observing correlations with disease phenotypes over extended periods, making it difficult to identify causal drivers of aging and rejuvenation. Somatic cells age but lack the ability to rejuvenate, hindering the study of cellular rejuvenation processes.
Solution
clock.bio addresses these challenges by utilizing human induced pluripotent stem cells (hiPSCs) and a proprietary "aging-in-a-dish" model to study cellular rejuvenation. The company force-ages hiPSCs and triggers their self-rejuvenation mechanisms, enabling the identification of genes causally relevant for cell rejuvenation through unbiased CRISPR screens. This technology allows for a comprehensive decoding of rejuvenation biology across the entire genome within a 12-month timeframe. By harnessing the regenerative capabilities of hiPSCs, clock.bio aims to develop novel treatments that prevent age-related diseases and extend healthspan.
Target Audience
clock.bio's primary target audience includes researchers and pharmaceutical companies focused on developing treatments for age-related diseases and extending human healthspan.
Features
- Proprietary aging model that force-ages hiPSCs to trigger self-rejuvenation mechanisms.
- Unbiased CRISPR screens on large samples of hiPSCs to identify gene candidates causally relevant for cell rejuvenation.
- "Aging-in-a-dish" model to study human aging in a controlled cell culture environment.
- Technology to decode the biology of human rejuvenation across the entire genome in 12 months.